BR-115

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameBR-115
Drug Alias NameCMG-6-A-19CMG6A19BR-115BR115
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsTumor-associated antigen modulators
TargetsT cell surface glycoprotein CD3Tumor-associated antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanMacauHong Kong +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChengdu Chimagen Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang BioRay Biopharmaceuticals Co LtdChengdu Chimagen Biosciences Co LtdHisun Biopharmaceutical Co Ltd
Inactive CompaniesBioRay Pharmaceutical Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A